Truist Financial Raises Eli Lilly and Company (NYSE:LLY) Price Target to $892.00

Eli Lilly and Company (NYSE:LLY) had its price target boosted by Truist Financial from $850.00 to $892.00 in a report released on Wednesday, Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other analysts have also recently weighed in on LLY. Barclays upped their target price on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the company an overweight rating in a research note on Wednesday, February 7th. JPMorgan Chase & Co. upped their price objective on Eli Lilly and Company from $775.00 to $850.00 and gave the company an overweight rating in a research note on Friday, March 15th. Bank of America increased their target price on Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a buy rating in a report on Friday, March 1st. Morgan Stanley increased their target price on Eli Lilly and Company from $805.00 to $950.00 and gave the stock an overweight rating in a report on Friday, February 16th. Finally, Wells Fargo & Company increased their target price on Eli Lilly and Company from $700.00 to $825.00 and gave the stock an overweight rating in a report on Tuesday, February 6th. Three investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of Moderate Buy and an average price target of $757.95.

Eli Lilly and Company Stock Down 2.8 %

LLY opened at $734.97 on Wednesday. Eli Lilly and Company has a 1-year low of $419.80 and a 1-year high of $800.78. The company has a current ratio of 1.35, a quick ratio of 0.73 and a debt-to-equity ratio of 1.90. The stock has a market capitalization of $698.52 billion, a price-to-earnings ratio of 108.24, a P/E/G ratio of 1.50 and a beta of 0.37. The business has a 50 day moving average of $761.75 and a 200-day moving average of $670.56.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Tuesday, April 30th. The company reported $2.58 earnings per share for the quarter, beating the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The company had revenue of $8.77 billion during the quarter, compared to analysts’ expectations of $8.94 billion. During the same period in the prior year, the business earned $1.62 earnings per share. Eli Lilly and Company’s revenue for the quarter was up 26.0% compared to the same quarter last year. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 13.83 earnings per share for the current year.

Institutional Investors Weigh In On Eli Lilly and Company

A number of institutional investors have recently made changes to their positions in the stock. Versant Capital Management Inc raised its stake in shares of Eli Lilly and Company by 1.8% in the first quarter. Versant Capital Management Inc now owns 736 shares of the company’s stock valued at $573,000 after buying an additional 13 shares during the period. Moseley Investment Management Inc. raised its stake in shares of Eli Lilly and Company by 0.4% in the first quarter. Moseley Investment Management Inc. now owns 3,890 shares of the company’s stock valued at $3,027,000 after buying an additional 14 shares during the period. CGN Advisors LLC raised its stake in shares of Eli Lilly and Company by 1.4% in the first quarter. CGN Advisors LLC now owns 1,001 shares of the company’s stock valued at $779,000 after buying an additional 14 shares during the period. Twin Peaks Wealth Advisors LLC raised its stake in shares of Eli Lilly and Company by 2.0% in the first quarter. Twin Peaks Wealth Advisors LLC now owns 718 shares of the company’s stock valued at $559,000 after buying an additional 14 shares during the period. Finally, Pitti Group Wealth Management LLC raised its stake in shares of Eli Lilly and Company by 0.8% in the first quarter. Pitti Group Wealth Management LLC now owns 1,673 shares of the company’s stock valued at $1,271,000 after buying an additional 14 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.